Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 8/20 | 0.34 |
| ▸ | PGK1 | P00558 | 3/20 | 0.34 |
| ▸ | PGK2 | P07205 | 3/20 | 0.34 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.32 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.32 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.32 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2262063 | 0.84 | S1PR1 (0.31) | KAT6AGGPS1 | |
| Hydrochloric Acid SCHEMBL2264057 | 0.83 | ACP3 (0.41) | ACP3GGPS1 | |
| Hydrochloric Acid SCHEMBL2259177 | 0.79 | ACP3 (0.34) | ACP3 | |
| Hydrochloric Acid SCHEMBL2262064 | 0.79 | S1PR1 (0.34) | KAT6AGGPS1CYP2D6 | |
| Hydrochloric Acid SCHEMBL2462471 | 0.79 | DRD2 (0.36) | — | |
| Hydrochloric Acid SCHEMBL2892897 | 0.78 | ACP3 (0.39) | ACP3 | |
| Hydrochloric Acid SCHEMBL2259577 | 0.77 | ACP3 (0.38) | ACP3 | |
| Hydrochloric Acid SCHEMBL2264240 | 0.75 | ACP3 (0.37) | ACP3 | |
| Hydrochloric Acid SCHEMBL2899630 | 0.75 | ACP3 (0.43) | ACP3PGK1PGK2 | |
| Hydrochloric Acid SCHEMBL2260159 | 0.74 | ALDH1A1 (0.49) | ACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090259042-A1 | ELECTROCHROMIC COMPOUNDS | NTERA LIMITED (IE) | 2009-10-15 | — | — | US | claimed |
| US-20060110638-A1 | Electrochromic compounds | NTERA LIMITED (IE) | 2006-05-25 | — | — | US | claimed |
| EP-1443091-A1 | Electrochromic compounds | Ntera Limited (IE) | 2004-08-04 | — | — | EP | claimed |
| US-20090259042-A1 | ELECTROCHROMIC COMPOUNDS | NTERA LIMITED (IE) | 2009-10-15 | — | — | US | disclosed |
| US-7567371-B2 | Electrochromic compounds | NTERA LIMITED (IE) | 2009-07-28 | — | — | US | disclosed |
| US-20060110638-A1 | Electrochromic compounds | NTERA LIMITED (IE) | 2006-05-25 | — | — | US | disclosed |
| EP-1594938-A1 | ELECTROCHROMIC COMPOUNDS | Ntera Limited (IE) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004067673-A1 | ELECTROCHROMIC COMPOUNDS | NTERA LIMITED (IE) | 2004-08-12 | — | — | WO | disclosed |
| EP-1443091-A1 | Electrochromic compounds | Ntera Limited (IE) | 2004-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090259042-A1 | ELECTROCHROMIC COMPOUNDS | ETV6, HCN2, EED | ACP3 2868/4885PGK1 1700/4885PGK2 1137/4885 |
| US-20060110638-A1 | Electrochromic compounds | ETV6, HCN2, EED | ACP3 2868/4885PGK1 1700/4885PGK2 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.